Georgia’s Expanded Medical Cannabis Law Takes Effect
On Wednesday, a new state law reshaping Georgia’s medical cannabis program went into effect, marking a significant shift from the previous low‑THC oil framework. The legislation, officially titled the “Putting Georgia’s Patients First Act,” was passed during the 2026 legislative session and aims to reduce barriers that have long limited patient access.
Key Changes in the New Law
The most notable update is the removal of the “low THC” designation, which previously capped products at 5 percent THC. Under the revised system, patients can purchase up to 12,000 milligrams of cannabis‑derived product at a time, measured in milligrams rather than percentages. This change aligns dosing with conventional pharmaceutical practices and eliminates confusion over potency.
The law also broadens the range of qualifying conditions, adding lupus and irritable bowel disease to the list, and removes the requirement that certain illnesses such as cancer or AIDS be classified as “severe or end stage” to qualify for treatment.
For adults aged 21 and older, the statute now permits the purchase of oil and products intended for dry‑herb vaporization. Smoking cannabis remains prohibited under state law. Additionally, the legislation reduces the mandatory distance between dispensaries and sensitive locations like schools and places of worship, bringing those requirements in line with regulations for alcohol retailers.
Impact on Patients and Providers
Gary Long, CEO of Botanical Sciences—a Georgia‑based cultivator, processor, and dispensary operator with five locations and a sixth slated to open in Augusta later this summer—described the overhaul as a modernization that brings Georgia’s program closer to those in other states. He noted that the previous low‑THC model limited both potency options and delivery methods, curbing interest among many potential patients. Long predicts the revised framework could triple the number of registered patients by mid‑2027; as of Tuesday, the state had approximately 36,600 active enrollees.
Dr. Tiffanni Forbes, an internal medicine physician and certified cannabis doctor practicing in Fayetteville, welcomed the shift to milligram‑based dosing. She explained that patients often struggled to interpret percentage‑based labels, leading to uncertainty about appropriate dosing. The new approach, she said, provides clearer guidance while still allowing for variation in potency based on total THC content.
Continued Advocacy Efforts
While advocates celebrate the expanded access, they caution that further work remains. Yolanda Bennett, a patient and co‑head of the Georgia Medical Cannabis Society, expressed enthusiasm for the recent changes but emphasized that upcoming legislative sessions will focus on securing insurance coverage, safeguarding patients residing in public housing, and overturning restrictions on outdoor consumption of medical cannabis.
Steph Sherer, founder and president of Americans for Safe Access, highlighted the potential ripple effect of the federal rescheduling of medical cannabis announced earlier in April. That move allows independent pharmacies to dispense cannabis products and strengthens patients’ ability to invoke protections under the Americans with Disabilities Act and related civil rights statutes. Sherer anticipates a broader push for uniform, nationwide access as patients gain confidence in asserting their rights.
This story was first published by Georgia Recorder.
For more information on the legislative changes and patient impact, see the original coverage: Here
